Skip to main content

Boston Scientific company profile

  • BSX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$44.34+0.32%Close 13 Nov 2026 · Market value $63.59B

About Boston Scientific

Boston Scientific develops and manufactures medical devices and therapies that help physicians diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Its core businesses are organized into two reportable segments, MedSurg and Cardiovascular, spanning business units including Endoscopy, Urology, Neuromodulation, Interventional Cardiology and Vascular Therapies, Electrophysiology, Cardiac Rhythm Management, and Interventional Oncology and Embolization. Key products include the WATCHMAN left atrial appendage closure devices, the FARAPULSE pulsed field ablation system and the SpyGlass single-use scopes. The company sells to hospitals, clinics, outpatient facilities and medical offices in 127 countries, largely through direct sales organizations and supplemented by distributors and dealers.

A summary of the business section of the company's latest annual report, filed 17 Feb 2026.

Company facts

TickerBSX · NYSE
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK885725
Latest annual report10-K, filed 17 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Michael F. MahoneyChairman, President & CEO · Director3.3M · < 1%Open-market purchase, 3 Aug 2026
Joseph M. FitzgeraldEVP & Group Pres, Cardiology670K · < 1%Code I, 31 Jul 2026
Daniel J. BrennanEVP and CFO555K · < 1%Option exercise, 19 Feb 2025
Jeffrey B. MirvissEVP&Pres, Periph Intervent365K · < 1%Sale under a 10b5-1 plan, 25 Feb 2025
Arthur C. ButcherEVP& Grp Pres, MedSurg & APAC268K · < 1%Shares withheld for tax, 2 May 2026
Jonathan R. MonsonEVP and CFO141K · < 1%Code I, 10 Aug 2026
Vance R. BrownEVP, GC and Corp. Secretary137K · < 1%Shares withheld for tax, 16 Feb 2026
John E. SununuDirector136K · < 1%Grant or award, 8 May 2025
Edward J. LudwigDirector62.3K · < 1%Open-market purchase, 31 Jul 2026
David S. WichmannDirector48.0K · < 1%Grant or award, 7 May 2026
Yoshiaki FujimoriDirector38.8K · < 1%Open-market sale, 29 Jul 2025
Ellen M. ZaneDirector24.1K · < 1%Grant or award, 7 May 2026
Susan E. MoranoDirector10.6K · < 1%Open-market purchase, 25 Aug 2026
Jessica L. MegaDirector8.2K · < 1%Grant or award, 7 May 2026
Cheryl PegusDirector5.9K · < 1%Open-market purchase, 20 May 2026
David C. HabigerDirector5.6K · < 1%Open-market purchase, 5 Aug 2026
Christophe P. WeberDirector879 · < 1%Grant or award, 7 May 2026
O'Connor Padraig AndrewEVP, Global Operations—Option exercise, 2 Sep 2026
Woodworth EmilySVP, Global Controller and CAO—Code I, 11 Aug 2026
O'Sullivan MiriamSVP, Chief HR Officer—Shares withheld for tax, 16 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

BSX in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.